Researchers report that vaccination against proteins found on profibrotic cells reduced liver and lung fibrosis in laboratory rodents.

The shift is likely to add to an ongoing shortage of primates used in labs, which could slow progress in future COVID-19 vaccine development and other areas.

How scientists aim to induce an immune response against addictive drugs

Researchers are turning to the immune system for help in treating addiction and preventing overdose.

Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?

The results could help guide the design of new vaccines for the disease.

Canada has ordered 76 million doses of Covifenz, the main ingredient of which was manufactured in the leaves of a tobacco relative.

Thousands of animals have had their shot already. How many more really need it?

RTS,S has several flaws but could still save tens of thousands of lives, experts say.

Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.  

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

Immune-response levels to the edible vaccine varied among the subjects, possibly due to differences in the gut microbiome.

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.  

This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

Scientists are on the hunt for a shot that will protect against not only SARS-CoV-2, but other members of its family that may emerge in the future.

Scientists use a protein found in mucus membranes to ferry vaccines to the lymph nodes.

By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.

It’s unclear how long protections against infection will last from the initial vaccinations, and health authorities say additional jabs will likely be necessary.